The global cell culture market is experiencing robust growth, driven by advancements in biotechnology, increased demand for biopharmaceuticals, and rising research activities in cancer and stem cell studies.
As per Future Market Insights (FMI)’ latest analysis, the global cell culture market is projected to total USD 44,593.1 million by 2034, up from USD 27,911.3 million in 2024. It will exhibit a CAGR of 4.7% from 2024 to 2034.
Several factors are set to fuel growth of the cell culture during the assessment period. These include escalating demand for biopharmaceuticals, advances in stem cell culture techniques, and growing interest in personalized medicines.
Cell cultures are becoming key for the production of biopharmaceuticals like monoclonal antibodies and insulin as well as vaccines. Thus, surging need for these biopharmaceuticals due to high chronic disease prevalence is set to propel cell culture demand globally.
Personalized medicine is a recent emerging medical practice that considers an individual’s genetic profile to diagnose, treat, and prevent disease. Researchers are creating customized and complex disease models of patients’ cells using cell culture, allowing an in-depth analysis of the patient’s unique genetic makeup.
This paves the way for developing more accurate drug testing models, increasing precision in drug development, reducing side effects, and increasing the probability of successful treatment.
With growing healthcare awareness and demand for vaccines, the market is projected to experience steady growth during the forecast period. Government support for drug discovery is also contributing to market growth.
The global market value is estimated to total USD 44,593.1 million in 2034. By phase, the commercial segment is projected to lead the market, growing at a CAGR of 3.9% during the forecast period. By end user, the biotechnology and pharmaceutical companies segment is set to grow at 6.0% CAGR through 2034. North America accounted for a prominent value share of 36.8% in 2023. The United States is set to record a CAGR of 3.0% through 2034. Revenue in China is poised to rise at 7.9% CAGR between 2024 and 2034.
Key companies profiled in the market study are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Lonza AG, Corning Incorporated, Eppendorf AG, and others.
Leading companies are implementing tactical approaches, such as mergers and acquisitions, business extensions, and new product creation, in order to broaden their range of offerings and fortify their position in the market.
In conclusion, the global cell culture market is on a growth trajectory fueled by increased demand for biopharmaceuticals, advances in personalized medicine, and expanding research activities in various therapeutic areas such as oncology and neurodegenerative diseases. As the market continues to evolve, key players are adopting innovative strategies to capitalize on emerging opportunities and drive further advancement in the field of cell culture.
